Putting the CHO Genome to Work: Illustrations to Increase Transgene Integration and Expression and to Improve Protein Processing
Geneva, Switzerland (PRWEB) May 22, 2012
Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the Company’s co-founder will be a keynote speaker at the 8th Annual Cell Line Development & Engineering Conference being held in San Francisco, California, USA. Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present new and unpublished data on Selexis’ core technology in his presentation, “Putting the CHO Genome to Work: Illustrations to Increase Transgene Integration and Expression and to Improve Protein Processing,” on Wednesday, June 6 at 4:00 PM.
Putting the CHO Genome to Work: Illustrations to Increase Transgene Integration and Expression and to Improve Protein Processing.
Incorporation of epigenetic regulatory DNA elements in expression vectors can prevent gene silencing and increase transcription rates. This has yielded stable and very high protein expression from CHO cells and increased therapeutic production in the bioreactor. Such progress has led to new currently emerging bottlenecks encompassing transgene genomic integration, protein secretion and processing, and cell physiology. We have determined the genome sequence of CHO cells used for pharmaceutical production and of derived producer clones. This allows cell engineering for increased genomic transgene integration by homologous recombination and for improved protein secretion and modifications. This presentation will illustrate how a systematic and multi-level approach can be used to improve the expression of pharmaceutical proteins.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.
For more information: